Search Results

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as Eli Lilly offers expanded Zepbound options; and struggling gene therapy biotech bluebird bio goes private in an attempt to stay solvent.

Tetra Bio-Pharma Inc. announced that its common shares began trading on the OTC Markets Group’s OTCPink Market in the United States under the symbol “TBPMF” effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the Toronto Stock Exchange under the ticker symbol “TBP”.

Acasti Pharma Inc. announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

IGC Pharma, Inc, announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

Tetra Bio-Pharma Inc. today announced the filing of three patent applications for its novel therapeutic, ARDS-003.

Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS).

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

Pharma-Bio Serv, Inc. announced that revenues for the three and six months ended April 30, 2024 were approximately $2.4 and $4.8, million, respectively, a decrease of approximately $2.2 and $4.0 million when compared to the same periods last year.